Anika Therapeutics Q4 Earnings Call Highlights

Anika Therapeutics (NASDAQ:ANIK) elaborate its fourth-quarter and full-year 2025 results and outlined its strategy for 2026 during its net telephone connected Thursday, highlighting commercial-channel growth, advancement connected its hyaluronic acerb (HA)-based pipeline, and operational initiatives aimed astatine improving profitability and currency generation.

New President and Chief Executive Officer Steve Griffin, who precocious stepped into the CEO role, credited erstwhile CEO Cheryl Blanchard—now Executive Chair—for repositioning the institution done portfolio actions and advancement crossed Integrity, Hyalofast, and Cingal. Griffin said the institution is present operating nether 3 strategical priorities:

• Revenue maturation driven by the commercialized channel, including planetary OA symptom portfolio enlargement and scaling Integrity to trim reliance connected OEM partners and amended diversification.

• Advancing the HA-based innovation pipeline, centered connected Integrity, Hyalofast, Cingal, and longer-term opportunities.

• Improving operational execution, including manufacturing productivity, yield, throughput, and a streamlined organizational operation to enactment profitability and currency generation.

→ Hinge Health’s AI Moat Might Be Its Patient Movement Data

Senior Vice President and Chief Accounting Officer Ian McLeod reported fourth-quarter 2025 full gross of $30.6 million, level year-over-year and accordant with the company’s revised expectations.

Commercial transmission gross roseate 22% to $13.3 million, driven by planetary execution and momentum successful Integrity. International OA symptom absorption gross accrued 28% successful the quarter, which absorption attributed to sustained marketplace stock gains for Monovisc and Cingal crossed respective regions.

→ Microsoft Is Sliding—An Insider Buy and Oversold Signals Are Changing the Setup

OEM transmission gross was $17.3 million, down 12% year-over-year. Management pointed to little year-over-year pricing for Monovisc and Orthovisc sold done J&J MedTech, portion noting that some products proceed to clasp market-leading positions. Non-orthopedic gross besides declined owed to little request for bequest products.

Profitability improved successful the quarter, with GAAP gross borderline rising to 63% from 56% a twelvemonth earlier, reflecting a much favorable premix and higher volumes that improved manufacturing throughput and productivity. Operating expenses were $18.5 million, up from $17.8 million, with SG&A expanding connected higher income and selling spending tied chiefly to Integrity growth, portion R&D held level astatine $6.5 million.